Update on immunoisolation cell therapy for CNS diseases.

Area of Science:

• Biomedical Engineering
• Neuroscience
• Drug Delivery

Background:

• The blood-brain barrier (BBB) significantly impedes drug delivery to the brain.
• Cellular implants offer a strategy to bypass the BBB for localized therapeutic molecule production and delivery.
• Polymer encapsulation, termed immunoisolation, protects xenogeneic cells within semipermeable membranes.

Purpose of the Study:

• To review advancements in cell immunoisolation for treating central nervous system (CNS) diseases.
• To discuss device configurations and membrane manufacturing for immunoisolatory implants.
• To highlight the application of immunoisolation in preclinical models of neurodegenerative diseases.

Main Methods:

• Utilizing semipermeable membranes to encapsulate therapeutic cells, allowing nutrient and oxygen exchange while blocking immune components.
• Developing and characterizing implantable devices for cell-based therapy.
• Evaluating immunoisolation strategies in preclinical models, including Alzheimer's and Huntington's disease.

Main Results:

• Immunoisolation successfully protects encapsulated cells from host immune rejection.
• The technology enables the use of non-human cells, eliminating the need for host immunosuppression.
• Demonstrated potential in preclinical models for delivering therapeutic molecules across the BBB.

Conclusions:

• Cell immunoisolation is a promising approach for treating CNS diseases by overcoming the BBB.
• Advances in device design and membrane technology are crucial for clinical translation.
• This strategy offers a viable alternative to systemic drug delivery and chronic immunosuppression.